Natural History Observational Study of MPS IIIa in SMC

Prospective, Natural History Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)

To characterize the clinical course of mucopolysaccharidosis type IIIA (MPS IIIA), and identify potential endpoints for future treatment trials.

Study Overview

• Status: Not yet recruiting
• Conditions: Sanfilippo Syndrome A
• Intervention / Treatment: Other: assessment

• Study Type: Observational
• Enrollment (Anticipated): 25

Contacts and Locations

• Study Contact: Name: SungYoon Cho; Phone Number: +82-2-3410-3537; Email: nadri1217@naver.com
• Study Contact Backup: Name: MinSun Kim; Phone Number: +82-2-3410-3537

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Initial patient eligibility is based on patient age and on a confirmed diagnosis of MPS IIIA.

Description

Inclusion Criteria:

• Confirmed diagnosis of MPS IIIA
• Has the ability to comply with protocol requirements, in the opinion of the investigator

Exclusion Criteria:

• Patient's assent is unattainable, or the patient's parent(s), or patient's legally authorized representative(s) is/are unable to understand the nature, scope, and possible consequences of the study, or do/does not agree to comply with the protocol defined schedule of assessments.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
No treatment; This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral, and imaging measures.	Other: assessment; Physical, developmental, neurological, behavioral, and neurocognitive assessments

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Bayley Scales of Infant Development-III/Kaufman Assessment Battery for Children-II (BSID-III/KABC-II) Age-Equivalent Scores	The Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III) is an individually administered test designed to assess the developmental functioning of infants and toddlers. The Bayley-III assesses development in five areas: cognitive, language, motor, social-emotional, and adaptive behavior. Children under the age of 3 will be tested for this. The Kaufman Assessment Battery for Children-Second Edition (KABC-II) is a clinical instrument for assessing cognitive development. Children over the age of 3 will be tested for this. Raw scores will be converted to age- equivalent scores to measure ability, skill, and knowledge, expressed as the age at which most individuals reach the same level (age norm; range: 0, unbound ). A positive value indicates improvement. The BSID-III and KABC-II age- equivalent scores will be based on the cognitive domain and average non-verbal age-equivalent score, respectively.	Baseline, 12 months, and 24 months
Change From Baseline in Vineland Adaptive Behavior Scales-II (VABS-II) Age-equivalent Scores	The age equivalent score represents the age in months of the typical and normal individual who would achieve the same result as the one who was tested. The age equivalent scores are assessed by Vineland Adaptive Behavior Scales, Expanded Interview Form, Second edition (VABS-II). The Vineland is designed to measure the adaptive behavior of individuals from birth to age 90. The Vineland-II contains 5 domains each with 2-3 subdomains. The main domains are Communication, Daily Living Skills, Socialization, Motor Skills, and Maladaptive Behavior. A positive value indicates improvement in health and cognition.	Baseline, 12 months, and 24 months
Change from Baseline in MPS health Assessment Questionnaire, Sanfilippo Behavior Rating Scale	Change from baseline in the SBRS scale assessed by parent report using the Sanfilippo Behavior Rating Scale form.	Baseline, 12 months, and 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Imaging characteristics	MRI will be used to assess changes in the size of various organs affected by the disease, including the brain, liver, and spleen.	Baseline, 12 months
Echocardiography	2-D Echocardiography will be used to assess heart valve abnormalities and ventricular hypertrophy.	Baseline, 6 months, 12 months, and 24 months
Hearing assessments	The function of hearing will be assessed using Auditory Brainstem Response (ABR).	Baseline, 12 months, and 24 months
Sleep habits	Patient sleep habits will be assessed using Children's Sleep Habits Questionnaire (CSHQ).	Baseline, 12 months, and 24 months
Ophthalmology assessments	Change from Baseline in lens opacification	Baseline, 12 months, and 24 months
Change From Baseline in Quality of Life (ITQoL/PedsQL) Questionnaire	Infant Toddler Quality of Life (ITQoL): The ITQoL Questionnaire is a generic, validated health status measure for children including items and scales to measure aspects of physical functioning, development, pain, mood, behavior, general health, and impact on parents. A positive value indicates improvement. Pediatric Quality of Life Inventory (PedsQL): Pediatric Quality of Life Inventory (PedsQL) is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. Lower scores indicate better functioning.	Baseline, 12 months, and 24 months

Collaborators and Investigators

• Sponsor: Samsung Medical Center
• Investigators: Study Director: SungYoon Cho, Samsung Medical Center

Study record dates

Study Major Dates

• Study Start (Anticipated): June 30, 2021
• Primary Completion (Anticipated): July 28, 2023
• Study Completion (Anticipated): July 28, 2024

Study Registration Dates

• First Submitted: April 28, 2021
• First Submitted That Met QC Criteria: June 6, 2021
• First Posted (Actual): June 9, 2021

Study Record Updates

• Last Update Posted (Actual): June 9, 2021
• Last Update Submitted That Met QC Criteria: June 6, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Disease; Genetic Diseases, Inborn; Connective Tissue Diseases; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Mucinoses; Mucopolysaccharidoses; Syndrome; Mucopolysaccharidosis III
• Other Study ID Numbers: SMC-2020-10-164-003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No